This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Anemia; hemochromatosis	Hypoxia-inducible factor 2 α (EPAS1; HIF2A); solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 (SLC11A2; DMT1)	Studies in mice suggest that upregulating HIF2A could help treat anemia, whereas inhibiting the transcription factor could help decrease iron absorption to treat iron accumulation disorders such as hemochromatosis. In mice, specific <i>hif2a</i> deletion led to lower expression of <i>dmf1</i> , the principal intestinal iron transporter, and decreased serum and liver iron levels compared with what was seen in wild-type controls. Next steps could include screening for compounds that modulate HIF2A activity and testing them in models of iron disorders.	Patent and licensing status unavailable	Mastrogiannaki, M. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online April 6, 2009; doi:10.1172/JCI38499 Contact: Carole Peyssonnaud, University Paris Descartes, CNRS, Paris, France e-mail: carole.peyssonnaud@inserm.fr
SciBX 2(15); doi:10.1038/scibx.2009.623 Published online April 16, 2009				